Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Defence Therapeutics Inc

Healthcare CA DTC

0.51CAD
-0.04(7.27%)

Last update at 2026-06-24T18:39:00Z

Day Range

0.480.52
LowHigh

52 Week Range

0.501.05
LowHigh

Fundamentals

  • Previous Close 0.55
  • Market Cap29.83M
  • Volume28067
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.06005M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax - -13.19304M -6.86778M -7.34400M -2.85925M
Minority interest - - - - -
Net income - -13.19304M -6.76278M -7.34400M -2.85925M
Selling general administrative 1.94M 8.44M 2.71M 3.35M 1.70M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - 0.09M 0.01M 0.00000M -
Ebit - - - - -
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income - -12.82188M -6.54536M -7.32013M -2.85925M
Other operating expenses - - - - -
Interest expense - 0.40M 0.26M 0.00000M -
Tax provision - 0.00000M -0.10500M 0.00000M -
Interest income - 0.02M 0.00681M 0.00000M -
Net interest income - -0.37597M -0.25612M 0.00000M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue - 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses - 12.82M 6.55M 7.32M 2.86M
Cost of revenue - - - - -
Total other income expense net - 0.00480M -0.06630M -0.02387M -
Discontinued operations - - - - -
Net income from continuing ops - -13.19304M -6.76278M -7.34400M -2.85925M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 0.48M 3.53M 0.72M 5.61M 1.91M
Intangible assets - 0.04M 0.05M 0.05M 0.05M
Earning assets - - - - -
Other current assets - - - - -
Total liab 4.06M 1.97M 1.11M 0.12M 0.05M
Total stockholder equity -3.58423M 1.57M -0.38756M 5.49M 1.86M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - - - - -
Capital stock 19.24M 16.95M 9.33M 7.97M 2.40M
Retained earnings -29.80809M -16.90718M -10.51567M -3.53261M -0.67336M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.06M 2.79M 0.51M 5.45M 1.87M
Cash and equivalents - - - - -
Total current liabilities 4.05M 0.22M 1.11M 0.12M 0.05M
Current deferred revenue - - - - -
Net debt 1.65M - - - -
Short term debt - - - - -
Short long term debt 1.71M - - - -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets 0.21M 3.43M 0.67M 5.56M 1.87M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.10M 0.15M 0.03M - -
Long term debt - 1.75M - - -
Inventory - - - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.26M 0.10M 0.05M 0.05M 0.05M
Capital lease obligations 0.04M 0.00000M - - -
Long term debt total - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -0.20324M -0.06580M 0.00000M - -0.04602M
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings -0.00941M 2.35M 0.00000M - -
Total cash from financing activities 1.76M 10.01M 1.10M 5.88M 2.04M
Change to operating activities - - - - -
Net income -13.19304M -6.76278M -7.34400M -2.85925M -0.67318M
Change in cash -2.73638M 2.29M -4.94621M 3.59M 1.87M
Begin period cash flow 2.79M 0.51M 5.45M 1.87M 0.00077M
End period cash flow 0.06M 2.79M 0.51M 5.45M 1.87M
Total cash from operating activities -4.28838M -7.65743M -6.04439M -2.28965M -0.13283M
Issuance of capital stock 1.89M 8.25M 1.10M 2.76M 2.28M
Depreciation 0.09M 0.01M 0.00000M - -
Other cashflows from investing activities - - - - -
Dividends paid 0.00000M 0.00000M 0.00000M - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - -
Change to netincome - - - - -
Capital expenditures 0.20M 0.07M 0.00000M 0.00000M 0.05M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.58M -1.36158M 0.93M -0.03641M 0.05M
Stock based compensation 5.84M 0.30M 0.37M 0.61M 0.18M
Other non cash items 0.40M 0.26M - - 0.31M
Free cash flow -4.49162M -7.72323M -6.04439M -2.28965M -0.17885M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
DTC
Defence Therapeutics Inc		 -0.04 7.27% 0.51 - - - 89.80 -9.991
DRUG
Bright Minds Biosciences Inc		 -0.85 0.90% 94.04 - - - 13.50 -0.098
METX
METX		 - -% 1.99 - - - 72.00
TELI
Telescope Innovations Corp.		 0.06 7.23% 0.89 - - 4.32 6.45 4.32 -1.62
LOBE
Lobe Sciences Ltd		 - -% 0.09 - - 2.44 15.58 5.75 1.64

Reports Covered

Stock Research & News

View All

Profile

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.

Defence Therapeutics Inc

7171 Rue Frederick-Banting, Montreal, QC, Canada, H4S1Z9

Key Executives

Name Title Year Born
Mr. Sebastien Plouffe CEO, President & Director 1972
Mr. Arnab Kumar De A.C.M.A., C.M.A., C.P.A., CGMA, M.B.A. CFO & Corporate Secretary NA
Dr. Mark Lambermon Ph.D. Head of Quality & Operations NA
Dr. Maxime Parisotto Chief Scientific Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions